Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we will assume that you are happy to receive all cookies and you will not see this message again. Click 'Find out more' for information on how to change your cookie settings.

The manipulation of pre-mRNA to alter gene transcript splicing patterns offers considerable potential for many genetic disorders. In particular, the targeted removal of one or more exons from a gene transcript can skip over, or compensate for, disease-causing mutations. Duchenne muscular dystrophy (DMD), the most common and severe form of muscular dystrophy, is one such disorder that could benefit from this strategy. Splicing modulation can convert a DMD phenotype into the less severe allelic Becker-like phenotype. Recent studies using antisense oligonucleotide-targeted exon skipping to induce near normal dystrophin in vivo in animal models, and in vitro in DMD cell lines, highlight the promise of this approach. On the basis of these successes, human clinical trials could be realized in the near future.

Original publication

DOI

10.1016/j.coph.2005.06.001

Type

Journal article

Journal

Curr Opin Pharmacol

Publication Date

10/2005

Volume

5

Pages

529 - 534

Keywords

Animals, Dystrophin, Genetic Therapy, Humans, Muscular Dystrophy, Duchenne, Oligonucleotides, Antisense, RNA Splicing, RNA, Small Nuclear